Promising Data in Prostate Cancer Top SPT Week in Review

5. FDA Grants Priority Review to Keytruda for First-Line Treatment of Head and Neck Cancer

The supplemental Biologics License Application was filed based on positive overall survival data from a phase 3 clinical trial for pembrolizumab in the treatment of recurrent or metastatic head and neck squamous cell carcinoma. Read more.

4. Study Finds Cancer Patients with HIV Can Benefit from Immunotherapy

Immunotherapy may become a viable option for patients with cancer infected with HIV. Read more.

3. FDA OKs Split-Dosing Regimen for Multiple Myeloma Treatment

The new approval allows for daratumumab (Darzalex) to be administered as a split infusion over 2 consecutive days. Read more.

2. Boomerang Effect Of Gene Therapy on Oncology Contracting

The economics of one and done gene therapies dictate a revenue model that requires outcomes-based risk. Read more.

1. Potential Metastatic Prostate Cancer Therapy Achieves Primary Trial Endpoints

If approved, apalutamide (Erleada) plus androgen deprivation therapy would offer an additional treatment option for patients with metastatic castration-sensitive prostate cancer. Read more.



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Although there have been links between esophageal cancer and drinking hot tea, this was the first study to examine a specific temperature.
A phase 3 study compared overall survival and cardiac safety between biosimilar trastuzumab (Ontruzant) and the reference medicine.
Top news of the week from Specialty Pharmacy Times.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.